Navigation Links
Trading Halted Today in Questcor Pharmaceuticals Common Stock
Date:5/6/2010

UNION CITY, Calif., May 6 /PRNewswire-FirstCall/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that NASDAQ has halted trading of Questcor's common stock pending news. The Peripheral and Central Nervous System Drugs Advisory Committee to the U.S. Food and Drug Administration (FDA) meets today to review and discuss the Company's supplemental New Drug Application (sNDA) to market H.P. Acthar® Gel (repository corticotrophin injection) for the treatment of infantile spasms.

Conference Call on Monday, May 10, 2010

Questcor will host a conference call and webcast to discuss the results of the FDA Panel meeting on Monday, May 10, 2010 at 4:30 p.m. Eastern / 1:30 p.m. Pacific. Don Bailey, President and Chief Executive Officer; Steve Cartt, Executive Vice President & Chief Business Officer; Dr. David Young, Chief Science Officer; and Dr. Jason Zielonka, Senior Vice President and Chief Medical Officer will participate. The dial-in number for the conference call is 877-941-9205 for domestic participants and 480-629-9835 for international participants.

A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will be available for seven days. This replay can be accessed by dialing 800-406-7325 for domestic callers and 303-590-3030 for international callers, both using passcode 4292117#. To access the live webcast of the call, go to Questcor Pharmaceuticals' website at www.questcor.com. An archived webcast will also be available at www.questcor.com.

About Questcor

Questcor Pharmaceuticals, Inc. is a pharmaceutical company that markets H.P. Acthar® Gel (repository corticotropin injection). H.P. Acthar Gel ("Acthar") is an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis ("MS") and to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that is due to lupus erythamatosus. In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms ("IS"), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. The Company also markets Doral® (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MyPunchbowl Inks Deal with Oriental Trading Company
2. ADVENTRX Reverse Split Effective; Trading on Adjusted Basis Begins Today
3. Unilife Corporation Commences Trading on the NASDAQ Global Market Under the Ticker Symbol UNIS
4. NASDAQ Trading for Oxygen Biotherapeutics, Inc. Shares to Begin January 15, 2010
5. KV Pharmaceutical Receives Permission from NYSE for its Securities to Continue Trading on the NYSE until March 31, 2010
6. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
7. Rx for Africa, Inc. Now Trading Under New Symbol (RXAF.PK)
8. Physicians Foundation Warns of Potential Impact From New Medicare Cuts Effective Today
9. Catalyst Pharmaceutical Partners to Present Today at 2010 Epilepsy Pipeline Update Conference
10. Elsevier is Meeting Todays Medical Students Needs With Online, Mobile and Print Tools
11. HearUSA Introduces AARP Hearing Care Program for Americans Aged 50-plus in Ohio Today
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2017)... , June 16, 2017  Exactly 50 years ago ... off what later became known as the San Francisco "Summer ... ) is unveiling two radical innovations in strategic market research ... This announcement marks the beginning of Northern Light,s "Summer of ... ...
(Date:6/14/2017)... , June 14, 2017  In 2016, ... Creative Startups pitch competition and came away with ... platform is described by Forbes as "entering the life ... Medical Association as teaching "empathy to medical professionals in ... startup was recently named a finalist for the Department ...
(Date:6/11/2017)... and Company (NYSE: LLY ) announced today ... an investigational treatment for the prevention of episodic and ... endpoints for galcanezumab compared to placebo at both studied ... REGAIN) will be presented today at the American Headache ... . "The detailed Phase 3 ...
Breaking Medicine Technology:
(Date:6/27/2017)... ... 27, 2017 , ... Atmosera , a premier Microsoft ... Services . The trusted, transparent, and secure solution for the cloud enablement of ... Atmosera’s next generation services include integrated capabilities for public, private, and hybrid Azure ...
(Date:6/27/2017)... ... 2017 , ... Today, June 27th is PTSD Awareness Day. Over half a ... receive adequate care due to lack of effective treatments, fear of stigma or insufficient ... left untreated, veterans are at an increased risk for self-destructive behavior, including alcohol/drug abuse, ...
(Date:6/26/2017)... ... 2017 , ... Torrance dentist, Dr. Robert Mondavi DDS , is now ... aspects of a person’s appearance. A healthy, radiant smile can make a person look ... everyone can have the smile of their dreams with cosmetic dentistry. , “The field ...
(Date:6/26/2017)... (PRWEB) , ... June 26, 2017 , ... ... according to a recent review of government data released by the United Soybean ... in management practices, Maryland’s soybean farmers have increased their productivity on less land ...
(Date:6/26/2017)... , ... June 26, 2017 , ... KICKICO , ... whitepaper that pledges to solve many catastrophic issues within funding campaigns. KICKICO developers ... The typical notion of crowdfunding - the raising of funds through the power of ...
Breaking Medicine News(10 mins):